Radiotherapy for Graves' orbitopathy: Results of a national survey

Strahlentherapie und Onkologie

Volumn 179, Issue 6, 2003, Pages 372-376

  Heyd, Reinhard ^a,f   Seegenschmiedt, M Heinrich ^b   Straßmann, Gerd ^c   Micke, Oliver ^d   Makoski, Hans Bruno ^e   Zamboglou, Nikolaos ^a  

^a Offenbach Hospital   (Germany)

^b ALFRIED KRUPP KRANKENHAUS   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e Hospital Duisburg North   (Germany)

^f Klinikum Offenbach GmbH   (Germany)

Author keywords

Benign disease; Graves' orbitopathy; Quality assurance; Radiation therapy

Indexed keywords

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; GERMANY; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; ORBIT DISEASE; QUALITY CONTROL; RADIATION DOSE FRACTIONATION; SALVAGE THERAPY; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0037642474     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-0911-9     Document Type: Article

References (27)

1. Anonymus. Classification of eye changes of Graves' disease. Thyroid 1992; 2:235-6.
2. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993;329:1468-75.
3. Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endcrinol Metab 1983;56: 1139-44.
4. Beckendorf V, Maalouf T, George J-L, et al. Place of radiotherapy in the treatment of Graves' orbitopathy. Int J Radiat Oncol Biol Phys 1999;43: 805-15.
5. Blank LE, Barendsen GW, Prummel MF, et al. Probable risk of tumor induction after retro-orbital irradiation for Graves' ophthalmopathy. Radiother Oncol 1996;40:187-9.
6. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-93.
7. Erickson BA, Harris GJ, Lewandowski MF, et al. Echographic monitoring of response of extraocular muscles to irradiation in Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1995;31:479-83.
8. Gripp S, Doeker R, Glag M, et al. Konventionelle und virtuelle Simulation bei der Retrobulbärbestrahtung. Strahlenther Onkol 2000;176:131-4.
9. Jacobson DH, Gorman CA. Diagnosis and management of endocrine ophthalmopathy. Med Clin North Am 1985;69:973-88.
10. Koelbl O, Knaus P, Pohl F, et al. Radiation-induced reduction of BMP-induced proteoglycan synthesis in an embryonal mesenchymal tissue equivalent using the chicken "limb bud" test. Strahlenther Onkol 2001;177: 432-6.
11. Leer JWH, van Houtte P, Daelaar J. Indication and treatment schedules for irradiation of benign diseases: a survey. Radiother Oncol 1998;48:249-57.
12. Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991;14:853-60.
13. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 355; 2000:1505-9.
14. Olivotto IA, Ludgate CM, Allen LHJ, et al. Supervoltage radiotherapy for Graves' ophthalmopathy: CCABC technique and results. Int J Radiat Oncol Biol Phys 1985;11:2085-90.
15. Otto E, Ochs K, Hansen C, et al. Orbital tissue-derived T-lymphocytes from patients with Graves' orbitopathy recognize autologous orbital antigens. J Clin Endocrinol Metab 1996;80:3045-50.
16. Palmer D, Greenberg P, Cornell P, et al. Radiation therapy for Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1987;13:1815-20.
17. Petersen IA, Kriss JP, McDougall IR, et al. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1990;19: 259-64.
18. Pfannenstiel P, Neidl K, Brunk G, et al. Wertigkeit und Indikation bildgebender Verfahren bei der Diagnostik und Verlaufskontrolle der endokrinen Orbitopathie. Akt Endokr Stoffw 1989;10:Sonderheft:161-8.
19. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989;321: 1353-9.
20. Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342:949-54.
21. Rödel F, Kamprad F, Sauer R, Hildebrandt G. Funktionelle und molekulare Aspekte der anti-inflammatorischen Wirkung niedrig dosierter Radiotherapie. Strahlenther Onkol 2002;178:1-9.
22. Seegenschmiedt MH, Katalinic A, Makoski H-B, et al. Strahlentherapie von gutartigen Erkrankungen: eine Bestandsaufnahme für Deutschland. Strahlenther Onkol 1999;175:541-7.
23. Seegenschmiedt MH, Keilholz L, Becker W, et al. Endokrine Orbitopathie: Vergleich der Langzeitergebnisse und Klassifikationen nach Radiotherapie. Strahlenther Onkol 1998;174:449-56.
24. Smitt MC, Donaldson SS. Radiation therapy for benign diseases of the orbit. Semin Radiat Oncol 1999;9:179-89.
25. Snijders-Keilholz A, Broerse JJ, Keilholz L, et al. Radiotherapy trial at two dose levels for Graves' orbitopathy. Radiother Oncol 1999;53: Suppl I:4.abstract.
26. Snijders-Keilholz A, De Kreizer RJW, Goslings BM, et al. Probable risk of tumour induction after retroorbital irradiation for Graves' ophthalmopathy. Radiother Oncol 1996;38:69-71.
27. Trott K-R, Kamprad F. Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiother Oncol 1999;51:197-203.